miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway.
Kuroda. Kengo K; Fukuda. Tomokazu T; Krstic-Demonacos. Marija M; Demonacos. Constantinos C; Okumura. Kazuhiko K; Isogai. Hiroshi H; Hayashi. Miwa M; Saito. Kazuki K; Isogai. Emiko E
Key Findings
- LL-37 and its analogue FF/CAP18 increase miR-663a levels in HCT116 colon cancer cells.
- Higher miR-663a reduces CXCR4 expression, lowers Akt signaling, and activates p21, leading to G2/M cell‑cycle arrest.
- Over‑expressing miR-663a or treating with LL-37 slows tumor growth in vitro and in mouse models.
Practical Outcomes
- For biohackers, the main takeaway is that LL-37 may have anti‑cancer properties mediated by miR-663a, but there is no human dosing guidance or safety data yet. It highlights a potential new pathway to explore for cancer prevention, but practical use would require much more research before any self‑experimentation.
Summary
The study shows that the natural antimicrobial peptide LL-37 can boost a small RNA called miR-663a in colon cancer cells, which then shuts down a cancer‑promoting receptor (CXCR4) and stops the cells from dividing. This effect was seen both in lab dishes and in mice, suggesting LL-37 might have anti‑cancer activity, but the work is still early‑stage and done in cell models.
Abstract
Antimicrobial peptides (AMPs) play important roles in the innate immune system of all life forms and recently have been characterized as multifunctional peptides that have a variety of biological roles such as anticancer agents. However, detailed mechanism of antimicrobial peptides on cancer cells is still largely unknown. miRNA array and real-time qPCR were performed to reveal the behavior of miRNA in colon cancer HCT116 cells during the growth suppression induced by the AMPs. Establishment of miR-663a over-expressing HCT116 cells was carried out for the evaluation of growth both in vitro and in vivo. To identify the molecular mechanisms, we used western blotting analysis. miR-663a is upregulated by administration of the human cathelicidin AMP, LL-37, and its analogue peptide, FF/CAP18, in the colon cancer cell line HCT116. Over-expression of miR-663a caused anti-proliferative effects both in vitro and in vivo. We also provide evidence supporting the view that these effects are attributed to suppression of the expression of the chemokine receptor CXCR4, resulting in the abrogation of phosphorylation of Akt and cell cycle arrest in G2/M via p21 activation. This study contributes to the understanding of the AMPs' mediated anti-cancer mechanisms in colon cancer cells and highlights the possibility of using AMPs and miRNAs towards developing future strategies for cancer therapy.
Study Information
pubmed
2017
2017-01-07T00:00:00.000Z
10.1186/s12885-016-3003-9
38
45